THE WHITE PAPER

Why Women’s Heart Health Belongs in the GLP-1 Coverage Conversation

Cardiovascular risk can rise in midlife, while many benefit designs still evaluate GLP-1 coverage through a diabetes or weight-loss lens. This white paper helps employers understand why this issue is changing, why it matters for plan sponsors, and why employer-specific data should come before any benefit decision. 

The first step is not changing the benefit. The first step is understanding your population. 

Fill out the form below to read the white paper.

Women’s heart health is becoming a benefits question

LucyRx Heart Health

Cardiovascular disease is the leading cause of death in women. 

For many women, risk begins to rise in midlife, during perimenopause and menopause. These changes can affect metabolism, body composition, insulin resistance, and cardiovascular risk. 

At the same time, many employer plans still evaluate GLP-1 coverage through a diabetes or weight-loss lens. 

Certain GLP-1s now carry an FDA-approved cardiovascular indication for adults with established cardiovascular disease and overweight or obesity. That means this is no longer just a weight-loss coverage question.  

It is a women’s heart health issue with a clear benefits implication. 

What you’ll learn:

This white paper explains:

  • why women’s heart health belongs in the GLP-1 coverage conversation  
  • how perimenopause and menopause can affect cardiometabolic risk  
  • why many benefit designs may not fully see this window  
  • what changed with certain GLP-1s and cardiovascular risk  
  • why this issue should be evaluated before employers make benefit changes  
  • how employers can use population-specific data before making benefit changes

Why read this white paper?

Industry averages can provide context, but they cannot answer the most important question:  What does this mean for your plan?

Employers need a clearer way to understand: 

  • how this issue may show up in their population
  • what the plan may already be spending  
  • which questions should be evaluated before benefit decisions are made  
  • what data can help frame the next conversation 

This white paper gives HR, benefits, finance, and clinical leaders a clearer way to evaluate the issue before making a benefit change.

Who should read it?

  • HR and benefits leaders
    Understand why women’s heart health and GLP-1 coverage are becoming a more important benefits conversation.
  • Finance and plan sponsors
    See why the right starting point is population-specific data, not industry averages.
  • Brokers and consultants
    Use the framework to help clients move from a broad coverage question to a more targeted benefits conversation.
  • Medical leaders
    Review how certain GLP-1s, cardiovascular risk, and targeted coverage criteria are changing the employer decision.

Download the white paper

Women’s heart health belongs in the GLP-1 coverage conversation. But that does not mean employers need to move straight to broad coverage.

The first step is understanding the population.